THC + CBD for Chronic Kidney Disease
(POT-GFR-PK Trial)
Trial Summary
What is the purpose of this trial?
POT-GFR-PK is a single dose pharmacokinetic study oral tetrahydrocannabinol (THC) and cannabidiol (CBD) in healthy adult controls and individuals with chronic kidney disease including those treated with in-center hemodialysis.
Research Team
Michael Walsh, MD, PhD
Principal Investigator
McMaster University
Eligibility Criteria
This trial is for adults over 25 with chronic kidney disease, including those on hemodialysis. Participants must have a body mass index between 20 and 35, no drug dependence (except caffeine or nicotine), no recent cannabis use, and not be taking certain medications that interact with THC/CBD.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single dose of oral THC and CBD, followed by blood, urine, and dialysate sample collection
Follow-up
Participants are monitored for safety and effectiveness after treatment, including adverse events and vital signs
Treatment Details
Interventions
- Tetrahydrocannabinol-Cannabidiol Combination
Find a Clinic Near You
Who Is Running the Clinical Trial?
McMaster University
Lead Sponsor
Center for Medicinal Cannabis Research
Collaborator